Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey
| Autor: | Klang Shmuel, Lapidot Tair, Megiddo Dalia, Naparstek Yaakov |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male 0301 basic medicine Microbiology (medical) medicine.medical_specialty Adolescent Endemic Diseases Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) medicine.medical_treatment 030106 microbiology Mucous membrane of nose nasal spray Microbiology Medication Adherence Young Adult 03 medical and health sciences Hypromellose Derivatives 0302 clinical medicine prevention Nasal powder Virology Internal medicine Mass gathering medicine Humans low pH Prospective Studies 030212 general & internal medicine Israel Administration Intranasal Original Research SARS-CoV-2 business.industry COVID-19 Nasal Sprays Odds ratio Middle Aged Infection rate Hypromellose Infectious Diseases Nasal spray Female Observational study Powders business Research Article |
| Zdroj: | Expert Review of Anti-Infective Therapy article-version (VoR) Version of Record |
| ISSN: | 1744-8336 1478-7210 |
| DOI: | 10.1080/14787210.2021.1908127 |
| Popis: | Objectives: Bney Brak city tops Israel’s COVID-19 infection rate and mortality. Before the Jewish New Year (two-day gathering) SARS-CoV-2 PCR positivity rates were 17.6% and reached 28.1% two weeks later Taffix – an innovative nasal powder creates a protective gel over the nasal mucosa blocking viruses from infecting nasal cells, was tested for efficacy in preventing SARS CoV2 infection. Methods: In a prospective users survey, 243 members of an ultra-orthodox community that participated in two days prayers were followed for 14 days following this ‘superspread’ event. Eighty-three used Taffix throughout holiday’s prayers and the following two weeks (ITT). Eighty-one used it regularly (PP). Two used it rarely if at all. The remaining 160 did not use Taffix. Results: After 14 days, 0/81 (0%) of (PP) Tafffix users, 2/83 (2.4%) of (ITT) Taffix users and 16/160 (10%) nonusers were infected. Odds ratio for infection among Taffix users was 0.22, a reduction of 78% (95%CI 1%–95%). No side effects reported. Conclusion: Taffix could be an additional tool against COVID19 spread, in addition to recommended safety measures. This is the first time that a prevention measure of SARS-CoV-2, beyond the use of masks, has proved effective. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|